Clinical labs face interruptions, staffing shortages

By Rebekah Moan, contributing writer

October 9, 2020 -- The Association for Molecular Pathology (AMP) has released the preliminary results of its August 2020 SARS-CoV-2 testing survey for clinical laboratories showing labs continue to experience supply chain interruptions and are now also facing significant staffing shortages. However, the demand for molecular diagnostic testing has increased.

The 100-question survey assessed several aspects of testing SARS-CoV-2: sample types, patient populations, methodologies, validation, performance, supply chain, public health reporting, laboratory workforce, and reimbursement. The survey responses came from 113 representatives affiliated with U.S.-based academic medical centers, commercial reference laboratories, public health laboratories, and community hospitals.

More than half (54%) of the respondents said testing demand was currently higher than their capacity, and they anticipate demand will continue to rise, especially with the fall and winter influenza season.

While demand keeps rising, staffing has not -- 85% of respondents have shortages and 66% do not have enough qualified clinical laboratory technologists/scientists. In addition, more than half (53%) do not have enough clinical laboratory technicians.

Based on the most recent survey results, as well as an earlier April survey, the AMP has two new recommendations:

  1. Ensure that regulatory requirements are not duplicative or burdensome. Keep the U.S. Centers for Medicare and Medicaid Services (CMS) as the regulatory agency responsible for lab oversight, as specified by the CLIA program.
  2. Support laboratory workforces through better collaboration and communication between public health, clinical laboratories, and relevant government agencies.

The AMP's previous five recommendations still stand:

  1. Reassessing the type and location of SARS-CoV-2 testing services needed
  2. Reprioritizing supply allocations based on clinical testing needs
  3. Increasing transparency, communication, and real-time transmission of information between laboratories and suppliers
  4. Ensuring real-time coordination among laboratories to offset excess capacity
  5. Standardizing agency reporting format and processes

The AMP will continue to review the pandemic's effects on clinical practice, regulatory policy, and reimbursement.

"These survey results will be fundamental to informing potential legislation and other initiatives that could significantly improve response to the current and future pandemics," said Dr. Karen Weck, AMP president and director of the molecular genetics lab at the University of North Carolina Chapel Hill.

Could COVID-19 end standoff on tests developed in laboratories?
During the COVID-19 pandemic, research and clinical laboratories have been working overtime to develop tests that would help them identify and understand...
World market outlook: COVID-19 testing evolves rapidly, lessons sink in
Worldwide, COVID-19 testing volume was on target to grow 25%-30% from May to June, reports Kalorama Information analyst Justin Saeks.
AMP survey shows labs' struggles with COVID-19 supply shortages
A survey conducted by the Association for Molecular Pathology (AMP) illustrates the challenges clinical labs have faced in securing supplies for COVID-19...
Medical professionals struggling with anxiety, joblessness
A survey of over 1,200 healthcare providers in the U.S. has found growing levels of anxiety and unemployment caused by the COVID-19 pandemic.
Labs absorb revenue losses, adapt to a 'new normal'
Leaders in pathology describe how their practices are adapting to the COVID-19 pandemic in the face of fallen revenues and an uncertain future as U.S....

Copyright © 2020

Last Updated np 10/13/2020 3:14:49 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.